Thakurdesai A et al., 2024-05: First biopsy-confirmed case of severe hepatocellular liver injury from self-administered fenbendazole in a 67-year-old American woman, with liver tests normalising three months after she stopped.
We describe the first case of histologically confirmed severe drug-induced liver injury, hepatocellular pattern, associated with the self-administration of fenbendazole in a 67-year-old woman who presented with 2 weeks of jaundice.
Abstract
Thakurdesai A et al., 2024-05: First biopsy-confirmed case of severe hepatocellular liver injury from self-administered fenbendazole in a 67-year-old American woman, with liver tests normalising three months after she stopped. Study type: single case report, n=1, USA (University of Louisville). Dose not stated in the abstract captured; duration at least the weeks before presentation. Route oral. Other treatment: none stated in the abstract. Outcome: liver function tests normalised in 3 months after cessation. Funding: NIH grant P30 ES030283 (record field, GrantList). Declared conflicts: none captured in the record. Comparator: none. The authors note fenbendazole 'is not approved by the US Food and Drug Administration for human use'. Study type: case report.
